Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant with or without selumetinib in advanced breast cancer after aromatase inhibitor progression
2010-019965-27Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Fulvestrant + selumetinib with Fulvestrant + placebo (2 arms). Primary endpoint: Disease control. Started Nov 2010; status: completed.
02
Drugs
fulvestrantselumetinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-019965-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019965-27.